Dr. Hammers on the Future of Treatments for RCC

Hans J. Hammers, MD, PhD
Published: Thursday, Aug 10, 2017



Hans J. Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses the future of treatments for patients with renal cell carcinoma (RCC).

It is an exciting time in kidney cancer, explains Hammers. Ever since the approval of nivolumab (Opdivo), checkpoint inhibitors have continued to see excitement. However, the question remains to be: what is next for these treatments?

Nivolumab has shown durable response rates of around 20% but it is not enough to effectively treat patients with immunotherapy, states Hammers. Therefore, this has been looked at in combination with targeted agents, such as VEGF inhibitors.



Hans J. Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses the future of treatments for patients with renal cell carcinoma (RCC).

It is an exciting time in kidney cancer, explains Hammers. Ever since the approval of nivolumab (Opdivo), checkpoint inhibitors have continued to see excitement. However, the question remains to be: what is next for these treatments?

Nivolumab has shown durable response rates of around 20% but it is not enough to effectively treat patients with immunotherapy, states Hammers. Therefore, this has been looked at in combination with targeted agents, such as VEGF inhibitors.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™ Decision Points in Advanced NSCLC: Assessing Treatment Options Beyond Disease ProgressionNov 30, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x